How can the company wring the most value from Pyrukynd?
Will upping the dose and changing the primary endpoint pay off?
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
The company reports decent data with its Oxbryta follow-on, but still has much to prove.
Forma still hopes for accelerated approval of etavopivat, while Agios believes that taking its time with mitapivat will pay off.
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.